CTC
APLS

Central Trust Company’s Apellis Pharmaceuticals APLS Stock Holding History

Central Trust Company’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-27
Closed -$468 – 1416
2025
Q2 		$468 Hold
27
– – ﹤0.01% 1405
2025
Q1 		$591 Hold
27
– – ﹤0.01% 1401
2024
Q4 		$862 Hold
27
– – ﹤0.01% 1391
2024
Q3 		$779 Hold
27
– – ﹤0.01% 1339
2024
Q2 		$1.04K Hold
27
– – ﹤0.01% 1334
2024
Q1 		$1.59K Hold
27
– – ﹤0.01% 1294
2023
Q4 		$1.62K Hold
27
– – ﹤0.01% 1301
2023
Q3 		$1.03K Buy
+27
New +$1.19K ﹤0.01% 1308

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Central Trust Company's APLS Position: Q3 2025 in Review

Central Trust Company sold out of Apellis Pharmaceuticals (APLS) in Q3 2025, closing a stake of 27 shares — an estimated $468 sold.

Central Trust Company first reported a position in APLS in Q3 2023 and held it in 8 quarters. The position peaked at $1.62K in Q4 2023. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.

  • Central Trust Company reported no remaining Apellis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Central Trust Company sold 27 Apellis Pharmaceuticals shares in Q3 2025, an estimated $468.
  • Central Trust Company first reported a position in Apellis Pharmaceuticals in Q3 2023 and held it in 8 quarters.
  • Central Trust Company's Apellis Pharmaceuticals position peaked at $1.62K in Q4 2023.
  • 273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.

Based on Central Trust Company's 13F filing for Q3 2025, filed 6 Nov 2025.